Author/Authors :
Bahaaldin-Beygi ، Morteza Department of Microbiology - Islamic Azad University, Kerman Branch , Kariminik ، Ashraf Department of Microbiology - Islamic Azad University, Kerman Branch , Kazemi Arababadi ، Mohammad Department of Laboratory Sciences - Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Faculty of Paramedicine - Rafsanjan University of Medical Sciences
Abstract :
Aim: Chemokines, cytokines, and their related molecules play crucial roles in the fight against the hepatitis B virus (HBV) and its related complications. Royal jelly (RJ) is considered an immunomodulatory factor for humans. This clinical trial study aimed to explore the RJ effects on the relative expression of CCL2, CCL3, CCL8, IFN-β, NANOG, OCT4, BAX, and MAVS in chronic hepatitis B (CHB) patients. Methods: The CHB patients were under one month of RJ treatment, 1 g/d. The relative expressions of CCL2, CCL3, CCL8, IFN-β, NANOG, OCT4, BAX, and MAVS were evaluated using the real-time polymerase chain reaction (PCR) technique. Results: RJ feeding significantly increased the expression of BAX in the peripheral blood immune cells of CHB patients. However, relative expressions of CCL2, CCL3, CCL8, IFN-β, NANOG, OCT4, and MAVS were not altered following RJ feeding. Conclusion: RJ can modulate immune responses via induction of homeostasis in the peripheral blood immune cells of CHB patients. Reduced inflammation following RJ feeding may be a result of homeostasis in the peripheral blood immune cells.
Keywords :
Chronic hepatitis B , Royal jelly , Chemokine , Gene expression
